Promising Results for New Treatment for Thyroid Eye Disease

  • By Ben Glickman

Viridian Therapeutics, a biotechnology company based in Waltham, Mass., witnessed a surge in its stock after the successful trial of a new formulation for treating thyroid eye disease (TED).

Stock Performance

  • The stock experienced an 8.7% increase, reaching $20.88 during midday trading.
  • However, the shares have faced a decline of 29% this year.

VRDN-003: A Promising Monoclonal Antibody Treatment

  • Viridian Therapeutics introduced VRDN-003, a monoclonal antibody designed specifically for TED treatment.
  • One notable advantage of VRDN-003 is its extended half-life of 40 to 50 days.
  • This longer half-life is approximately four to five times longer than the company’s previous formulation, VRDN-001.

The Future of VRDN-003

  • Due to its compelling performance, VRDN-003 has been chosen as the primary candidate for subcutaneous development of TED treatments.
  • Viridian Therapeutics plans to commence the pivotal program for this treatment in mid-2024.
  • The extended half-life of VRDN-003 allows for less frequent dosing, potentially reducing it to once every eight weeks.

Understanding Thyroid Eye Disease (TED)

  • TED is an autoimmune disease that results in inflammation and swelling around the eye.
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Recall Notice: Quaker Oats Company

Next Post

Global Regulators Secure a Win

Related Posts